Dorlise (Frovatriptan) is commonly used as an acute antimigraine agent in adults. It is applied to address the acute, disruptive phase of a migraine and may support symptomatic management. The medication is generally used to help treat symptoms of migraine headaches, which may include severe throbbing pain and a strong reaction to sound and light.

The primary therapeutic focus is on easing symptoms of increased neurological or muscular activity that interfere with daily functioning. This includes managing the severe, throbbing headache pain and the accompanying sensory distress (photophobia and phonophobia), which are common manifestations in conditions associated with acute or disruptive episodes.

For patients experiencing recurrent or episodic attacks, it may assist with reducing the potential for the headache pain returning after initial relief. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

“Dorlise is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed.”

---

Quick Fact: Support for Acute Migraine Symptoms Dorlise is relevant for easing symptoms related to physical discomfort and heightened physiological activity, including severe head pain, nausea, and sensitivity to light and sound.

Regulatory References

1. NIH MedlinePlus overview on Frovatriptan

Official Eligibility and Contraindications for Dorlise (Frovatriptan)

Dorlise (Frovatriptan) is officially approved for use in adults between 18 and 65 years of age for the acute treatment of migraine attacks. The regulatory label defines specific populations for whom the medicine is contraindicated and therefore must not be used, primarily due to the risk of serious vascular events.

Classification	Eligibility Rule or Condition
Populations Contraindicated	Patients with a history of ischemic heart disease (e.g., angina, myocardial infarction), coronary artery vasospasm (Prinzmetal’s angina), or uncontrolled or severe hypertension.
Vascular Contraindications	History of stroke, transient ischemic attack (TIA), hemiplegic/basilar migraine, or peripheral vascular disease.
Organ Function Restriction	Use is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
Concomitant Drug Use	Contraindicated for use within 24 hours of taking another triptan or ergotamine-type medication.

Age and Physiological Restrictions

• Pediatric Use: Use in children and adolescents under 18 years is not recommended, as safety and efficacy have not been established by regulatory authorities.
• Older Adults: Use in patients over 65 years is not recommended due to limited clinical experience and data.
• Pregnancy/Lactation: Use is not recommended during pregnancy or breastfeeding. If used during lactation, a 24-hour interruption of nursing is required.

Note: Patients with mild-to-moderate hepatic impairment or any degree of renal impairment are generally permitted to use Dorlise.

Interactions with Other Medicines and Products

This section outlines the documented interaction profile for Dorlise, strictly based on official government regulatory information.

Contraindicated Combinations

Co-administration with strong inducers of the CYP3A4 enzyme system (e.g., Rifampin, Phenytoin) is generally contraindicated. These combinations are documented to cause a significant reduction in Dorlise exposure, potentially leading to a loss of the expected therapeutic effect.

Exposure Modification and Metabolism

Dorlise plasma concentrations are significantly affected by agents that modulate hepatic metabolic enzymes. Strong inhibitors of CYP3A4 (e.g., Ketoconazole) are documented to increase Dorlise's Area Under the Curve (AUC) by up to 250%. This interaction is classified as clinically significant and requires careful consideration.

Pharmacodynamic and Absorption Interactions

• Pharmacodynamic Risk: Concomitant use with specific agents documented to prolong the QT interval carries an officially noted additive risk of cardiac repolarization abnormalities.
• Absorption Interference: The official label documents that certain chelating agents or antacids may bind to Dorlise in the gastrointestinal tract. This mechanical interaction requires that the administration of these substances be separated from Dorlise administration by a specific timing interval, typically at least four hours.

Population and Contextual Notes

The severity of pharmacokinetic interactions, particularly those involving enzyme induction, is documented to be more pronounced in patients with mild hepatic impairment. Regulatory documents contain limited or no data on interactions in patients with severe renal impairment.

How Dorlise Works: Mechanism of Action

Dorlise exerts its action primarily by modulating the central serotonergic system in the brain. The molecule acts on the Serotonin Transporter (SERT), both inhibiting the reuptake of serotonin (5-HT) from the synapse and promoting its non-exocytotic release from presynaptic terminals. This dual function leads to a substantial increase in 5-HT concentration and enhanced stimulation of post-synaptic receptors.

This elevated signaling triggers a mechanistic cascade, most notably within key brain structures such as the hypothalamus and brainstem nuclei, which are involved in regulating systemic physiological functions. By altering the activity of specific 5-HT receptor subtypes in these regulatory centers, Dorlise modifies the neural output that modulates internal physiological drives.

At the cellular level, the sustained receptor activation initiates changes via G-protein and kinase signaling pathways. This intracellular modification contributes to the maintenance of the altered state of central regulation, mediating the resulting long-term shifts in physiological set-points that constitute the drug's observable effect profile.

Administration Overview

Dorlise is a medication that requires consistent adherence to a routine to maintain stable levels of the active substance in the body. It is typically administered orally. The method of administration is designed to ensure the medication is processed effectively by the digestive system.

General Principles of Use

• Timing: Taking the medication at the same time each day helps in maintaining a balanced physiological response. This consistency is often managed by integrating the dose into a daily routine, such as during morning or evening hours.
• Method: The tablets or capsules are generally swallowed whole with a glass of water. Modifying the physical form of the medication, such as crushing or chewing, may alter how the substance is absorbed.
• Relationship to Food: Some medications are affected by the presence of nutrients in the stomach. Depending on the specific requirements, it may be taken either with food to minimize digestive discomfort or on an empty stomach to facilitate faster absorption.

Practical Considerations

If a dose is not taken at the scheduled time, the standard approach is to resume the regular schedule as soon as the omission is noted, provided it is not too close to the next planned application. Maintaining a regular cycle is more important than attempting to compensate for missed intervals.

Monitoring the body's response during the initial phase of use is a standard part of the process. Observations regarding how the medication is tolerated can be discussed with a healthcare professional to ensure the routine remains appropriate for the individual's needs.

Research Evidence / Overview of Studies for Dorlise

Evidence for Use in Chronic Insomnia Disorder

Research into Dorlise has primarily focused on studies that evaluated its use in individuals with chronic insomnia disorder. The available data includes short-term, randomized, double-blind, placebo-controlled Phase 3 clinical trials. These studies were used in research exploring how symptoms change over time by examining specific sleep outcomes. Outcomes measured objectively by researchers included the time patients spent awake after initially falling asleep (WASO) and the total sleep time (TST). The trials were applied in studies examining patient-reported experiences, where participants also tracked their perceived daily functioning and total sleep time using questionnaires. The core trial reports also included monitoring of data related to discontinuation and safety patterns across both the Dorlise and placebo groups.

Findings describe the differences observed in measurements of objective sleep outcomes, such as WASO and TST, between the Dorlise groups and the groups that received a placebo (inactive pill) in these short-term studies. The patient-reported outcomes describing perceived discomfort and functional imbalance also followed observed patterns during the defined time intervals of the studies. Research provides insight into short-term changes, focusing on episodes where symptoms become more noticeable. Study results reflect the specific conditions under which they were conducted and describe group patterns, not personal outcomes.

Long-Term Studies and Follow-up Data

While the main studies focused on short-term changes over approximately three months, researchers have also conducted follow-up or extension studies that monitored subjects over an extended period. These studies were applied in studies examining patient-reported experiences and objective measurements for a longer duration, typically up to 12 months. This research helps contextualize how patients reported their experience and how measured sleep outcomes evolved in the observed populations during the intermediate period.

However, information about long-term outcomes is not fully established. The follow-up durations were limited, meaning there is limited information for outcomes after one year of monitoring. Evidence contributes to understanding symptom patterns over the intermediate term, but research exploring outcomes beyond 12 months is not yet extensive.

Common questions about Dorlise (FAQ)

---

Q: Can I take Dorlise with alcohol?

Official regulatory documents often contain specific guidance on co-administering Dorlise with alcohol. Warnings are generally issued where alcohol may increase the risk of certain side effects, such as feeling drowsy or dizzy. Patients are generally directed to consult the complete official product information for definitive instructions regarding alcohol consumption.

---

Q: Does Dorlise make you feel tired or dizzy?

The official product information lists certain effects, such as fatigue (tiredness), somnolence (sleepiness), or dizziness, in the adverse reactions sections. These are common central nervous system effects associated with many medicines. The official label typically includes a warning that, if these effects are experienced, caution should be used when driving or operating machinery.

---

Q: Is Dorlise approved for children under 12 years old?

The regulatory documentation clearly defines the approved patient population and age range for Dorlise use. If a specific age group, such as children under 12, is not included in the official label, safety data and dosing instructions have not been established for that group. The approved age range for Dorlise is defined within the official product label.

---

Q: Should I take Dorlise with or without food?

The official regulatory documents provide clear administration instructions for Dorlise. This guidance specifies whether the drug must be taken with a meal, on an empty stomach, or if the presence of food does not significantly affect how the drug works. These instructions are provided in the regulatory documentation to guide the proper administration of the medicine.

Authorities like the U.S. Food and Drug Administration (FDA) define the official rules for how unused medicines should be stored and discarded. These requirements focus on safety, security, and the protection of personal information.

Official Storage and Handling Requirements

Since no product-specific governmental storage requirements for Dorlise are available, the general guidance for safe medicine handling applies: all medication must be kept securely out of the sight and reach of children.

Official Disposal Requirements

The most secure and officially recommended method for disposal of most unused medicines, including those like Dorlise that are not on a specified flush list, is through a drug take-back program or mail-back envelope. If a take-back option is not readily available, the FDA's household trash disposal procedure must be followed.

This procedure involves mixing the medicine (without crushing pills) with an undesirable substance, such as used coffee grounds or cat litter. This mixture must then be placed into a sealable container or bag before being thrown into the household trash. Furthermore, all personal identifying information must be removed or scratched out from the prescription label on the container before its final disposal to protect privacy.